Law and Order: Health Care [STAT Summit 2026 Review #27]

Report 27. Law and Order: Health Care

Part I. English Version

1. Event / Date & Time

Event: Law and Order: Health Care

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 11:50 AM EDT

2. Participants

Speakers

- Jacob Foster — Deputy Assistant Attorney General, National Fraud Enforcement Division, U.S. Department of Justice

Moderator

- Torie Bosch — Editor, First Opinion, STAT

3. Summary

Fraud Risks in Digital Health: New technologies can expand access but can also enable large-scale misuse of prescriptions, reimbursement and patient information.

Regulatory Enforcement: The Department of Justice described healthcare-fraud capabilities expanding into digital health, life sciences and AI-related misconduct.

Trustworthy Innovation: Effective oversight and timely disclosure were presented as essential to prevent misconduct from eroding public confidence in legitimate health technologies.

4. Main Discussion

Telehealth Fraud and Patient Harm

Foster cited a case in which a digital mental-health platform was used to distribute more than 40 million Adderall pills, rather than delivering appropriate care. He argued that the technology industry’s “move fast and break things” mindset is especially dangerous in medicine because the consequences include direct patient harm.

Foster argued that healthcare technology operates under a different risk calculus from ordinary consumer software. A “move fast and break things” mindset can expose patients to serious harm when products influence prescriptions, clinical information or access to treatment. He cited the conviction of a former digital-health executive associated with an online mental-health platform through which more than 40 million Adderall tablets were distributed, according to his account. He described harms alleged in that case as examples of why pharmaceutical and digital health businesses cannot regard aggressive growth as the overriding goal. The session treated fraud enforcement as a means to protect patients and the credibility of legitimate innovation, not as a general indictment of telemedicine or AI.

Foster described a digital mental-health business that prosecutors alleged was functioning as a vehicle for mass distribution of prescription stimulants, rather than delivering appropriate clinical care. He cited a conviction involving more than 40 million Adderall pills. In his account, warning signs included reports of harm to patients and a leadership attitude that celebrated rapid growth despite the risks. The case illustrated why familiar technology-industry rhetoric about moving fast can be dangerous when the product affects clinical decisions and controlled medicines. The conviction was discussed as a specific law-enforcement outcome, not evidence that digital-health models in general are fraudulent.

Enforcement Expansion and Life-Sciences Expertise

He described extending healthcare-fraud enforcement capabilities to Boston and San Francisco, bringing legal expertise closer to biotechnology and digital-health clusters. The department is also concentrating expertise related to life sciences and investigations under the Food, Drug, and Cosmetic Act within its healthcare-fraud functions.

The Department of Justice’s healthcare-fraud work was described as expanding in both geography and subject matter. Foster said specialized activity had expanded to Boston in the preceding year and San Francisco in the current year, locations where technology investors and life-sciences firms operate at scale. He also described concentrating expertise relating to life-sciences investigations and the Food, Drug, and Cosmetic Act within a healthcare-fraud team. These comments concerned the department’s enforcement priorities as presented by the official, rather than newly enacted substantive regulations. For industry, the implication was a closer convergence of clinical claims, digital platforms, fundraising, payment practices and potential criminal liability.

The Department of Justice’s healthcare fraud enforcement work was described as increasingly specialized in life sciences and digitally mediated care. Foster discussed expanding enforcement capacity in innovation hubs including Boston and San Francisco, and bringing expertise related to the Food, Drug, and Cosmetic Act into a coordinated structure. These changes reflected his view that prosecution teams need to understand product development, investment structures and software-mediated clinical workflows. For developers, the relevance is broader than billing accuracy: promotional representations, prescribing practices, referral incentives and the actual clinical service delivered can all become subjects of scrutiny if they misrepresent safety or appropriate use.

Self-Disclosure and AI Misuse

The conversation addressed how organizations should respond if automated tools introduce inaccurate diagnoses or billing, including early investigation and voluntary disclosure. Foster described corporate enforcement incentives for disclosing misconduct before it becomes known to authorities. He also discussed past cases involving misleading claims about treatments during COVID-19.

The conversation examined how billing data and anomalous utilization can provide leads while still requiring careful investigation. A practice that performs at an extreme percentile may reflect exceptional specialization or conduct that deserves scrutiny; an outlier alone is not proof of wrongdoing. Foster discussed using expertise in healthcare reimbursement and technologies to distinguish normal clinical variation from potentially manipulative schemes. This matters for AI-enabled systems, which may permit harmful practices to expand quickly across many patients or transactions. The department’s stated aim was to identify misconduct without conflating legitimate efficiency improvements with fraud. Companies deploying automation therefore need transparent practices, appropriate controls and records that can explain how decisions and transactions arise.

The exchange considered how companies might respond when a compliance issue is discovered. Foster emphasized the importance of meaningful self-disclosure and remediation, while distinguishing cooperation with authorities from attempts to hide problematic conduct. The moderator also asked about artificial intelligence, whose use in healthcare creates new possibilities for both efficiency and deception. An automated process does not eliminate responsibility for claims made to insurers or patients; the institution deploying it remains accountable for safeguards and oversight. The discussion did not prescribe a single technical AI standard, but it clearly treated governance, auditability and truthful representations as safeguards that allow credible innovation to proceed.

Protecting Innovation Through Accountability

Foster emphasized that enforcement is intended not to obstruct legitimate innovation but to prevent fraudulent actors from undermining confidence in telemedicine, AI and biotechnology. The emphasis was on protecting patients and the credibility of an expanding digital-health market.

Foster repeatedly linked enforcement to public acceptance of medical innovation. If patients experience new care models primarily through deceptive billing or unsafe prescribing, the resulting damage to trust may extend beyond one company. He suggested that enforcement capacity should evolve with telehealth, digital platforms and artificial intelligence, while keeping patient safety as its anchor. The session did not establish how every forthcoming technology would be policed and offered no blanket legal conclusion about specific business models. It instead framed integrity, documentation and responsible oversight as conditions for scaling technology in a heavily regulated sector. The argument illustrates why business incentives and scientific or clinical claims must be evaluated together.

The underlying argument was that enforcement and innovation need not be opposing goals. Foster said serious fraud can discredit new therapies and delivery tools by undermining patients’ confidence in the sector. Effective oversight should target harmful conduct while giving lawful developers a clearer basis for investing in new services. The biomedical policy implication lies in the design of incentives: growth, reimbursement and product claims should be connected to appropriate clinical care rather than rewarded solely for transaction volume. This perspective represented the speaker’s explanation of DOJ priorities and should not be mistaken for an exhaustive statement of current enforcement policy.

5. Insights

Compliance by Design: Digital-health R&D and commercialization can benefit from auditability and safeguards against inappropriate clinical or billing practices.

Implications for South Korea: Korea could consider clear oversight and incident-reporting pathways for AI-enabled healthcare tools and remote-care services.

Innovation and Accountability: Coordinated industry compliance and proportionate enforcement may protect patients while sustaining confidence in useful technologies.

Report 27. Law and Order- Health Care_eng.pdf

Download PDF • 68KB